Sanofi India has launched its diabetes drug Soliqua in India, a once-daily injectable combination drug containing insulin and GLP-1 receptor agonist lixisenatide. The medication is available at a therapy cost of Rs 1,850 per pen and is indicated for adults with obesity and type 2 diabetes to improve glycemic control.
